|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Athira Pharma, Inc. (ATHA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
30,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Athira Pharma is a late clinical-stage biopharmaceutical company. Co.'s primary candidate, fosgonimeton (ATH-1017), is a blood brain barrier-penetrating, small molecule hepatocyte growth factor (HGF)/MET positive modulator. The primary target indication is Alzheimer's disease (AD). Co.'s product candidate for its neuropsychiatric program is ATH-1020, which is a small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and to distribute to the central nervous system. Co. has several preclinical candidates for non-AD indications, including ATH-1019, which is being developed to address peripheral indications such as peripheral neuropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
605,686 |
685,698 |
2,157,060 |
| Total Buy Value |
$0 |
$1,462,896 |
$1,705,913 |
$6,104,477 |
| Total People Bought |
0 |
1 |
2 |
6 |
| Total Buy Transactions |
0 |
3 |
6 |
13 |
| Total Shares Sold |
0 |
13,264 |
13,264 |
36,879 |
| Total Sell Value |
$0 |
$38,598 |
$38,598 |
$102,919 |
| Total People Sold |
0 |
5 |
5 |
6 |
| Total Sell Transactions |
0 |
5 |
5 |
12 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Church Kevin |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-05 |
4/A |
S |
$2.91 |
$7,019 |
D/D |
(2,412) |
80,256 |
|
- |
|
| Gengos Andrew |
CFO AND CHIEF BUSINESS OFFICER |
• – – |
2024-01-05 |
4/A |
S |
$2.91 |
$3,515 |
D/D |
(1,208) |
83,804 |
|
- |
|
| Worthington Mark |
General Counsel |
• – – |
2024-01-05 |
4 |
S |
$2.91 |
$7,019 |
D/D |
(2,412) |
34,452 |
|
- |
|
| Lenington Rachel |
Chief Operating Officer |
• – – |
2024-01-05 |
4 |
S |
$2.91 |
$7,019 |
D/D |
(2,412) |
13,395 |
|
- |
|
| Litton Mark James |
Chief Executive Officer |
• • – |
2024-01-05 |
4 |
S |
$2.91 |
$14,026 |
D/D |
(4,820) |
144,397 |
|
- |
|
| Church Kevin |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-04 |
4/A |
A |
$0.00 |
$0 |
D/D |
10,000 |
82,668 |
|
- |
|
| Gengos Andrew |
CFO AND CHIEF BUSINESS OFFICER |
• – – |
2024-01-04 |
4/A |
A |
$0.00 |
$0 |
D/D |
5,000 |
85,012 |
|
- |
|
| Worthington Mark |
General Counsel |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
36,864 |
|
- |
|
| Lenington Rachel |
Chief Operating Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
15,807 |
|
- |
|
| Moebius Hans |
Chief Medical Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
91,482 |
|
- |
|
| Litton Mark James |
Chief Executive Officer |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
149,217 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2023-12-29 |
4 |
B |
$2.38 |
$390,211 |
I/I |
163,954 |
5,402,964 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2023-12-28 |
4 |
B |
$2.44 |
$999,419 |
I/I |
409,598 |
5,239,010 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2023-12-27 |
4 |
B |
$2.28 |
$73,266 |
I/I |
32,134 |
4,829,412 |
2.25 |
- |
|
| Church Kevin |
Chief Scientific Officer |
• – – |
2023-11-20 |
4 |
A |
$1.34 |
$4,552 |
D/D |
3,397 |
72,668 |
|
- |
|
| Gengos Andrew |
See Below |
• – – |
2023-06-07 |
4 |
B |
$3.36 |
$51,445 |
D/D |
15,000 |
80,012 |
2.74 |
- |
|
| Gengos Andrew |
See Below |
• – – |
2023-06-05 |
4 |
B |
$3.00 |
$135,150 |
D/D |
45,000 |
65,012 |
2.74 |
- |
|
| Moebius Hans |
Chief Medical Officer |
• – – |
2023-06-02 |
4 |
OE |
$1.35 |
$10,641 |
D/D |
7,882 |
81,482 |
|
- |
|
| Gengos Andrew |
See Below |
• – – |
2023-06-02 |
4 |
B |
$2.75 |
$56,422 |
D/D |
20,012 |
20,012 |
2.74 |
- |
|
| Worthington Mark |
General Counsel |
• – – |
2023-05-18 |
4 |
A |
$2.41 |
$18,718 |
D/D |
7,767 |
26,864 |
|
- |
|
| Church Kevin |
Chief Scientific Officer |
• – – |
2023-05-18 |
4 |
A |
$2.41 |
$1,950 |
D/D |
809 |
69,271 |
|
- |
|
| Moebius Hans |
Chief Medical Officer |
• – – |
2023-05-18 |
4 |
A |
$2.41 |
$18,711 |
D/D |
7,764 |
73,600 |
|
- |
|
| Johnson James A |
Director |
– • – |
2023-03-29 |
4 |
B |
$2.40 |
$12,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Church Kevin |
Chief Scientific Officer |
• – – |
2023-03-24 |
4 |
OE |
$1.35 |
$8,654 |
D/D |
6,410 |
68,462 |
|
- |
|
| Gengos Andrew |
See Below |
• – – |
2023-01-05 |
4 |
S |
$2.91 |
$3,515 |
D/D |
(1,208) |
83,804 |
|
- |
|
96 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
